Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference
(firmenpresse) - TUSTIN, CA -- (Marketwired) -- 11/05/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will present a company update at the Credit Suisse 2013 Healthcare Conference on Tuesday, November 12, 2013 at 1:00 PM Mountain Time (3:00 PM Eastern Time) at The Phoenician Hotel, Scottsdale, Arizona.
Peregrine's presentation will be webcast live and available for replay for 30 days at:
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at .
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2013 - 15:00 Uhr
Sprache: Deutsch
News-ID 1279782
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
